HR-4993-119
Ordered to be Reported in the Nature of a Substitute (Amended) by the Yeas and Nays: 41 - 0.
Sponsored by Brian Fitzpatrick (R-PA)
What it does
This bill would amend the Medicare program (Title XVIII of the Social Security Act) to allow external infusion pumps and certain associated drugs to qualify as covered durable medical equipment (DME), even if they do not currently meet Medicare's "appropriate for use in the home" requirement. Coverage would apply when three conditions are met: the FDA-approved prescribing information requires administration by or under a health care professional's supervision, a qualified home infusion therapy supplier administers or supervises the drug in the patient's home, and the drug is infused at least 12 times per year intravenously, subcutaneously, or at rates requiring a pump. The bill would also require the Secretary of Health and Human Services to notify patients of cost-sharing differences between home infusion therapy and other care settings.
Who benefits
Medicare beneficiaries who require frequent infusion therapy (at least 12 times per year) and could receive treatment at home rather than in a clinical setting. Patients with conditions such as immune deficiencies, infections, cancer, or chronic diseases requiring IV medications. Qualified home infusion therapy suppliers and their employees, who would gain a broader Medicare-reimbursable patient base. Caregivers and family members of patients who would benefit from reduced travel burdens. Rural and mobility-limited patients for whom travel to infusion centers is especially difficult.
Who is hurt
Hospital outpatient infusion centers and infusion clinics that may lose patients — and associated Medicare reimbursements — to home-based alternatives. Physicians and clinical staff at facility-based infusion sites who could see reduced patient volume. Medicare's trust fund, which may face increased costs if home infusion coverage expands utilization beyond what would otherwise occur. Taxpayers who fund Medicare, to the extent new coverage increases program spending. Patients who choose home infusion but are not fully informed of cost-sharing differences may face unexpected out-of-pocket costs.
Supporters argue
Supporters argue that Medicare's current DME rules create an arbitrary barrier that forces patients requiring professionally supervised infusion therapy to receive treatment in expensive clinical settings when safe, qualified home administration is available. They contend that home infusion therapy can reduce overall Medicare costs by substituting lower-cost home care for higher-cost hospital outpatient or inpatient settings, and that the bill's three-part eligibility test — FDA labeling, qualified supplier supervision, and minimum infusion frequency — provides meaningful safeguards against inappropriate use.
Opponents argue
Opponents argue that relaxing the "appropriate for use in the home" standard for drugs explicitly requiring professional supervision could increase Medicare spending without clear evidence that home settings consistently match the safety outcomes of supervised clinical environments. They contend that the 12-infusions-per-year threshold and supplier self-supervision may be insufficient guardrails, and that expanding coverage without a formal CBO cost estimate or pilot program risks adding an open-ended entitlement to a Medicare program already facing long-term solvency challenges.